{"analyses":[{"ciLowerLimit":"0.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.2","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.026","paramType":"Difference in Percentages","paramValue":"3.5","statisticalMethod":"Miettinen & Nurminen"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"},{"groupId":"OG001","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"604"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"description":"Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.","groups":[{"description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.","id":"OG000","title":"9vHPV Vaccine - Base Study"},{"description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.","id":"OG001","title":"Placebo - Base Study"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 vaccination and had available temperature data.","reportingStatus":"POSTED","timeFrame":"up to 5 days after any vaccination - Base Study","title":"Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}